CRISPR THERAPEUTICS AG Accounts Payable
CRISPR THERAPEUTICS AG (CRSP) had Accounts Payable of $11.31 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-03
- 2026-06-30: Accounts Payable, Current $11.31M.
- 2026-03-31: Accounts Payable, Current $13.65M.
- 2025-12-31: Accounts Payable, Current $11.14M.
- 2025-09-30: Accounts Payable, Current $11.80M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $11.31M 10-Q · filed 2026-08-03 |
| 2026-03-31 | $13.65M 10-Q · filed 2026-05-04 |
| 2025-12-31 | $11.14M 10-Q · filed 2026-08-03 |
| 2025-09-30 | $11.80M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $9.75M 10-Q · filed 2025-08-04 |
| 2025-03-31 | $13.06M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $14.71M 10-K · filed 2026-02-12 |
| 2024-09-30 | $15.58M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $9.45M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $16.46M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $38.15M 10-K · filed 2025-02-11 |
| 2023-09-30 | $26.15M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $27.59M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $45.15M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $27.43M 10-K · filed 2024-02-21 |
| 2022-09-30 | $32.11M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $25.24M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $27.11M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $14.82M 10-K · filed 2023-02-21 |
| 2021-09-30 | $10.17M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $10.14M 10-Q · filed 2021-07-29 |
| 2021-03-31 | $13.07M 10-Q · filed 2021-04-27 |
| 2020-12-31 | $9.09M 10-K · filed 2022-02-15 |
| 2020-09-30 | $19.02M 10-Q · filed 2020-10-28 |
| 2020-06-30 | $13.22M 10-Q · filed 2020-07-27 |
| 2020-03-31 | $11.28M 10-Q · filed 2020-04-28 |
| 2019-12-31 | $5.94M 10-K · filed 2021-02-16 |
| 2019-09-30 | $3.37M 10-Q · filed 2019-10-28 |
| 2019-06-30 | $7.14M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $7.13M 10-Q · filed 2019-04-29 |
| 2018-12-31 | $5.07M 10-K · filed 2020-02-12 |
| 2018-09-30 | $5.22M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $4.48M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $2.55M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $1.64M 10-K · filed 2019-02-25 |
| 2017-09-30 | $2.12M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $2.56M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $3.94M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $4.57M 10-K · filed 2018-03-08 |
| 2016-09-30 | $1.94M 10-Q · filed 2016-11-22 |
| 2015-12-31 | $1.58M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |